公告送出日期：2025年12月19日 1 公告基本信息 ■ 注：①根据中国创盈市场服务有限公司《关于2024年底及2025年深港通下的港股通交易日有关安排的通 知》等通知安排，2025年12月24日下午至2025年12月26日不提供港股通服务，2025年12月29日起照常开 通港股通服务。为满足投资者的投资需求，本基金自2025年12月29日起恢复办理申购、赎回业务，届时 本公司将不再另行公告。 ②场内简称：恒生红利ETF 2其他需要提示的事项 登录新浪财经APP 搜索【信披】查看更多考评等级 2.1投资者在2025年12月24日、2025年12月25日、2025年12月26日仍可进行本基金的二级市场交易。 2.2本基金自2025年12月29日起恢复办理申购、赎回业务，届时本公司将不再另行公告。本公告为因非 港股通交易日等日期安排暂停和后续恢复相关业务的说明，本基金如因其他原因暂停/恢复申购、赎回 业务，具体业务办理以相关公告为准。 2.3若港股通交易日安排、深圳证券交易所、香港联合交易所有限公司状况等发生变化，或根据法律法 规、基金合同等规定需要调整上述事项的，或中国证监会、证券交易所发布新的节假日放假和休 ...

Fund Overview - The fund is named "Huaxia Hang Seng Biotechnology Exchange-Traded Fund (QDII)" and aims to closely track the Hang Seng Biotechnology Index, which reflects the performance of the largest 50 biotechnology companies listed in Hong Kong [1][12] - The fund was established on September 29, 2021, and is managed by Huaxia Fund Management Co., Ltd. with China Agricultural Bank as the custodian [1][4] - As of June 30, 2025, the total fund shares amounted to 5,933,266,022 [1][19] Financial Performance - The fund reported a profit of approximately 1.79 billion RMB for the first half of 2025 [2] - The net asset value per share at the end of the reporting period was 0.7256 RMB, with a net value growth rate of 51.45% [14][19] - The fund's cumulative net value growth rate since inception is -27.44% [6][14] Investment Strategy - The fund employs a combination of strategies including full replication, alternative strategies, and derivatives to minimize tracking error and closely follow the benchmark index [1][12] - The fund's performance benchmark is the return of the Hang Seng Biotechnology Index, adjusted for valuation exchange rates [1][12] Market Context - The Hong Kong stock market showed strong performance in the first half of 2025, with significant inflows from southbound funds, particularly in sectors like AI technology, new consumption, and innovative pharmaceuticals [13][15] - The fund's investment operations were conducted with a focus on maintaining liquidity and stability, responding to investor subscriptions, redemptions, and adjustments in constituent stocks [13][14] Management and Compliance - Huaxia Fund Management Co., Ltd. is recognized as one of the largest ETF asset management companies in China, with a comprehensive product line covering various indices [5][8] - The fund management strictly adheres to relevant laws and regulations, ensuring fair treatment of all fund holders and maintaining transparency in operations [10][18]